Ursodeoxycholic acid (en UDCA) (UDCA), is the epimer of chenodeoxycholic acid and is a hydrophilic, non- cytotoxic bile acid . It is the least aggressive bile acid - a natural component of human bile and is contained in an amount of 1-5% of the total amount of bile acids in the human body.
| Ursodeoxycholic acid | |
|---|---|
 | |
| Chemical compound | |
| IUPAC | 3Ξ±, 7Ξ²-dihydroxy-5Ξ²-cholan-24-oic acid |
| Gross formula | C 24 H 40 O 4 |
| Molar mass | 392.56 g / mol |
| Cas | |
| PubChem | |
| Drugbank | |
| Classification | |
| ATX | |
| Dosage Forms | |
| capsules, suspension (infant form) | |
| Other names | |
| Ukrliv, Ursodex, Ursosan, Ursofalk, Ursokhol, Kholudeksan, Ursolizin, Urdoksa, Ursodez, Ursoliv Ursotsid, Exhol | |
Initially, ursodeoxycholic acid was recommended for the dissolution of gallstones and for the treatment of reflux gastritis. Currently, UDCA is considered the standard treatment for cholestatic liver diseases with an autoimmune component, such as, for example, primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), etc.
Content
Pharmacodynamics
Hepatoprotective agent, has a choleretic effect. It reduces the synthesis of cholesterol in the liver, its absorption in the intestine and its concentration in bile, increases the solubility of cholesterol in the biliary system, and stimulates the formation and excretion of bile . Reduces the lithogenicity of bile, increases the content of bile acids in it; causes increased gastric and pancreatic secretion, enhances lipase activity, has a hypoglycemic effect. Causes partial or complete dissolution of cholesterol stones during enteral use, reduces the saturation of bile with cholesterol, which helps mobilize cholesterol from gallstones. It has an immunomodulatory effect, affects the immunological reaction in the liver : reduces the expression of certain antigens on the hepatocyte membrane; affects the number of T-lymphocytes, the formation of IL-2, reduces the number of eosinophils [1] .
Indications
- biliary reflux gastritis ;
- primary biliary cirrhosis in the absence of signs of decompensation (symptomatic treatment) and other diseases caused by stagnation of bile [1] .
- alcoholic liver disease https://www.rlsnet.ru/regdoc/39918
Contraindications
- hypersensitivity ;
- X-ray positive (high in calcium) gallstones;
- non-functioning gall bladder ;
- acute inflammatory diseases of the gallbladder, bile ducts and intestines;
- decompensated liver cirrhosis ;
- severe impaired renal, liver , pancreas .
Ursodeoxycholic acid has no age restrictions in use, but children under the age of 3 years are recommended to use Ursofalk in the form of a suspension, as difficulties may arise when swallowing capsules [1] .
Pregnancy and lactation
The use of the drug during pregnancy and lactation is possible if the expected effect of therapy exceeds the potential risk to the fetus (no studies have been performed). For women of childbearing age, contraception is needed while taking the drug [2] .
Side effects
Diarrhea , nausea , pain in the epigastric region and right hypochondrium, calcification of gallstones, increased activity of hepatic transaminases, allergic reactions .
In the treatment of primary biliary cirrhosis, transient decompensation of cirrhosis of the liver may occur, which disappears after discontinuation of the drug [1] .
Link
Notes
- β 1 2 3 4 Description of the drug Ursofalk . Encyclopedia of drugs. Register of medicines of Russia.
- β Description of Ursodeoxycholic acid (Ursodesoxycholic acid) - Radar Encyclopedia: instructions for use of the drug Ursodeoxycholic acid and composition, reviews, contraindications ...